ADPT
Adaptive Biotechnologies CorporationAbout ADPT
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Company
- Headquarters
- Seattle, WA
- Employees
- 624 (2026)
- Listed
- Jun 27, 2019
- Exchange
- Nasdaq
- Website
- adaptivebiotech.com
- SEC industry
- Biological Products, (no Diagnostic Substances)
- Cylvex sector
- Health Care · Biotech
Biotech
- Market cap #23 of 146
- P/B #4 of 131
Ranked highest first among stocks Cylvex covers.
- AMGNAmgen Inc$258.6B+3.72%
- GILDGilead Sciences Inc$216.4B+4.18%
- MRNAModerna Inc$103.1B+13.10%
- ARGXargenx SE$58.57B+3.36%
- RVMDRevolution Medicines, Inc.$42.77B+2.74%
Financial summary
Related companies
About
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.